{
    "clinical_study": {
        "@rank": "6671", 
        "arm_group": [
            {
                "arm_group_label": "AKB-6548 (therapeutic dose)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AKB-6548 (supratherapeutic dose)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate the effect of single oral therapeutic and\n      supratherapeutic doses of AKB-6548 on the QT interval."
        }, 
        "brief_title": "Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Healthy, non-smoking males or females, 18 and 55 years of age, inclusive\n\n          -  BMI 18.0 and 32.0 kg/m2, inclusive\n\n          -  non clinically significant 12-lead ECG\n\n          -  heart rate of 45 to 90 beats per minute, inclusive\n\n          -  mean systolic blood pressure <141 mmHg and mean diastolic blood pressure < 90 mmHg\n\n        Key Exclusion Criteria:\n\n          -  history or presence of significant cardiovascular, pulmonary, hepatic, renal,\n             hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or psychiatric\n             disease\n\n          -  history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias, or\n             torsades de pointes, structural heart disease, or a family history of Long QT\n             syndrome\n\n          -  significant abnormalities in liver function tests\n\n          -  history of stomach or intestinal surgery or resection that would potentially alter\n             absorption and/or excretion of orally administered drugs\n\n          -  history of Gilbert's Syndrome\n\n          -  positive hepatitis panel\n\n          -  seizure disorder or receiving anti-epilepsy medication for seizure disorder\n\n          -  any acute or chronic condition that, in the opinion of the Investigator, may pose a\n             safety risk to a subject in this study or which would limit the subject's ability to\n             complete and/or participate in this clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062203", 
            "org_study_id": "AKB-6548-CI-0010"
        }, 
        "intervention": [
            {
                "arm_group_label": "AKB-6548 (therapeutic dose)", 
                "description": "Single oral dose of AKB-6548 at a therapeutic dose level", 
                "intervention_name": "AKB-6548 (therapeutic dose)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AKB-6548 (supratherapeutic dose)", 
                "description": "Single oral dose of AKB-6548 at a supratherapeutic dose level", 
                "intervention_name": "AKB-6548 (supratherapeutic dose)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Single oral dose of placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moxifloxacin", 
                "description": "Single oral dose of 400 mg moxifloxacin", 
                "intervention_name": "Moxifloxacin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Akebia", 
            "QT interval", 
            "TQT", 
            "pharmacokinetic", 
            "anemia", 
            "chronic kidney disease", 
            "CKD", 
            "chronic renal insufficiency", 
            "renal impairment", 
            "safety"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Evansville", 
                    "country": "United States", 
                    "state": "Indiana"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Single-Center, Partially Double-Blinded, Active and Placebo Controlled, Randomized 4-Way Crossover Study to Evaluate the Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Akebia Therapeutics", 
            "last_name": "Robert Shalwitz, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Placebo-corrected change-from-baseline QTcF (\u0394\u0394QTcF) following AKB-6548 administration.", 
            "safety_issue": "Yes", 
            "time_frame": "multiple timepoint evaluations from pre-dose to 24 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062203"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Placebo-corrected change-from-baseline heart rate (HR), PR interval, QRS interval", 
                "safety_issue": "Yes", 
                "time_frame": "multiple timepoint evaluations from pre-dose to 24 hours post-dose"
            }, 
            {
                "measure": "Categorical outliers defined as QTcF >450 msec, 480 msec and 500 msec at any timepoint and change-from-baseline QTcF (\u0394QTcF) >30 msec (increased by 30 msec) and >60 msec", 
                "safety_issue": "No", 
                "time_frame": "multiple timepoint evaluations from pre-dose to 24 hours post-dose"
            }, 
            {
                "measure": "Categorical outliers for HR, PR interval, QRS interval", 
                "safety_issue": "No", 
                "time_frame": "multiple timepoint evaluations from pre-dose to 24 hours post-dose"
            }, 
            {
                "measure": "Frequency of T wave morphology changes", 
                "safety_issue": "Yes", 
                "time_frame": "multiple timepoint evaluations from pre-dose to 24 hours post-dose"
            }, 
            {
                "measure": "Placebo-corrected change-from-baseline QTcF (\u0394\u0394QTcF) following moxifloxacin administration", 
                "safety_issue": "No", 
                "time_frame": "multiple timepoint evaluations from pre-dose to 24 hours post-dose"
            }, 
            {
                "measure": "Safety parameters to include adverse events; changes in routine clinical laboratory measures including chemistry, hematology, and urinalysis; and clinically significant changes noted during physical examinations or in vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "from first dose of study medication through the final protocol required visit"
            }
        ], 
        "source": "Akebia Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Akebia Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}